



**Press release**  
Gothenburg, Sweden  
October 20, 2020. 10:30 CET

# Conference call interim report

**Invitation to attend CELLINK's conference call regarding presentation of the interim report September – August 2019/2020. The presentation will be held in English.**

Time: Thursday, October 22, 2020. 09:30 CET

For audio: +46 8 502 439 36. Conference ID: 839 363 608#

[Video link](#) to the presentation.

Participants from CELLINK are:  
Erik Gatenholm, CEO  
Gusten Danielsson, CFO

A press release with CELLINK's interim report will be published at 08.15 the same day.

Before the start of the conference call, presentation material will be available on the company's [website](#).

For further information, please contact:

**Erik Gatenholm, CEO**

Phone (Sweden): +46 73 267 00 00

Phone (US): +1 (650) 515 5566

Email: [eg@cellink.com](mailto:eg@cellink.com)

**Gusten Danielsson, CFO**

Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (857) 332 2138

Email: [gd@cellink.com](mailto:gd@cellink.com)

This information was submitted for publication, through the agency of the contact persons set out above, on October 20, 2020 at 10:30 CET.

## **About CELLINK**

Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK's products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 200 publications. CELLINK is creating the future of medicine.

Visit [cellink.com](http://cellink.com) to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.